Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide against rev from Human Immunodeficiency Virus Type 1 in the Adult Male Rat Following Single Injections and Continuous Infusion

An antisense phosphorothioate oligodeoxynucleotide 27-mer complementary to the rev gene mRNA of the human immunodeficiency virus (HIV-1) was administered to rats through intravenous injections and subcutaneous infusions in order to investigate the disposition of this compound. In addition, nonlethal toxic responses of the rat were evaluated. A biphasic plasma clearance with t1/2α of 20–25 min and t1/2β of 27–41 hr was observed. Single doses ranging from 35 to 3257 μg were examined, and the plasma concentration and area under the plasma concentration–time curve (AUC) were found to be directly proportional to the dose. Continuous subcutaneous infusion of 50 mg over 28 days was also examined. The oligonucleotide is completely eliminated in the urine over 3 days. Electrophoretic analysis demonstrated that the excreted compound has the same mobility and UV-absorbance profile as the administered compound. Measurement of accumulation and distribution into tissues revealed unique tissue-specific rates and extent ...